1. In Vivo

Boston Scientific Shuffles and Sells in Bid to Right Ship

Boston Scientific, in a bid to raise capital and focus its efforts, is selling off lower priority businesses as well as its stakes in nearly 100 private and public companies.

A year ago, Boston Scientific Corp. president and CEO Jim Tobin was outlining his steps to fix its newly acquired prize, Guidant, which he said had been languishing with operational and quality control problems, particularly in its much-prized ICD business. [See Deal] (See "How to Fix a Guidant: Boston Scientific's Tobin Opens Playbook," IN VIVO, December 2006 Also see "How To Fix A Guidant: Boston Scientific's Tobin Opens Playbook" - In Vivo, 1 December, 2006.)

While those clean-up activities are still underway, Boston Scientific management has spent the last few months looking within to find...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

Execs On The Move: June 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.